Depression is a widespread and serious global mental illness. Approximately 322 million people worldwide suffer from depression, which accounts for 4.4% of the total population. Currently, antidepressants are the preferred treatment for depression. However, clinical antidepressants such as selective 5-hydroxytryptamine reuptake inhibitors (SSRIs), and norepinephrine reuptake inhibitors (SNRIs) are commonly associated with serious side effects. As a result, it is crucial to explore new therapeutic targets for the treatment of depression. Our results indicate that Programmed Cell Death 4 (PDCD4) is an effective antidepressant target,
which holds important implications in the development of antidepressant drugs.